Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Plans Viread Filing For Hepatitis B By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data shows significant improvement in viral load in HBV patients treated with Viread versus Hepsera.

You may also be interested in...



Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Company also awaits August PDUFA date for the same indication in the United States.

Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Company also awaits August PDUFA date for the same indication in the United States.

Gilead Files Viread sNDA For Chronic Hepatitis B

New marketing application for the HIV therapy went to FDA Oct. 10, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel